Codexis, Inc. reported significant financial developments in its latest quarterly filing, revealing a total revenue of $15.3 million for the three months ended June 30, 2025, a 92% increase from $8.0 million in the same period last year. The company's product revenue rose by 18% to $7.4 million, while research and development revenue surged by 362% to $7.9 million, primarily due to increased activity from legacy agreements and a new licensing agreement. However, for the six months ended June 30, 2025, total revenue decreased by 9% to $22.9 million compared to $25.1 million in the prior year, attributed to variability in customer manufacturing schedules and clinical trial timelines.
The company’s operating expenses decreased by 8% to $28.2 million for the second quarter, driven by a 39% reduction in the cost of product revenue and a 21% decrease in selling, general, and administrative expenses. This led to a loss from operations of $12.9 million, a 43% improvement compared to a loss of $22.7 million in the same quarter of 2024. The net loss for the quarter was $13.3 million, or $0.16 per share, down from a net loss of $22.8 million, or $0.32 per share, in the prior year.
In terms of strategic developments, Codexis has made strides in its ECO Synthesis manufacturing platform, which focuses on the enzymatic synthesis of RNA interference therapeutics. The company completed the build-out of its ECO Synthesis Innovation Lab, which is expected to support the manufacture of good laboratory practice-grade siRNA for customers. Additionally, Codexis anticipates entering a partnership with a large-scale contract development and manufacturing organization to further enhance its offerings in RNAi manufacturing.
Operationally, Codexis reported a cash and cash equivalents balance of $26.8 million as of June 30, 2025, up from $19.3 million at the end of 2024. The company also saw a decrease in its employee headcount, which may reflect ongoing efforts to streamline operations. The total liabilities stood at $82.6 million, with long-term debt increasing to $39.4 million following the second tranche of a loan agreement with Innovatus Life Sciences Lending Fund I, LP.
Looking ahead, Codexis remains focused on leveraging its proprietary CodeEvolver technology platform to enhance its product offerings and expand its market presence. The company expects to continue investing in research and development to drive future growth, although it acknowledges the potential need for additional capital to support its strategic initiatives. The management's outlook suggests a cautious optimism as they navigate the complexities of the biopharmaceutical landscape while aiming to improve operational efficiencies and revenue generation.
About CODEXIS, INC.
Codexis is a biotechnology company specializing in enzyme engineering and biocatalysis for pharmaceutical manufacturing and RNAi therapeutics. Its proprietary CodeEvolver platform develops high-performance enzymes to improve drug synthesis efficiency, yield, and sustainability. The company offers enzymatic solutions, contract development, and manufacturing services, targeting large pharma clients and the growing RNAi market with a focus on scalable, environmentally friendly processes.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.